Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Deferred Taxes (2024 - 2025)

Silence Therapeutics' Deferred Taxes history spans 2 years, with the latest figure at $1000.0 for Q3 2025.

  • For Q3 2025, Deferred Taxes fell 97.96% year-over-year to $1000.0; the TTM value through Dec 2025 reached $11000.0, down 98.7%, while the annual FY2025 figure was $11000.0, 98.7% down from the prior year.
  • Deferred Taxes for Q3 2025 was $1000.0 at Silence Therapeutics, down from $10000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $324000.0 in Q4 2024 and bottomed at $1000.0 in Q3 2025.